OFX-514

About Oxalo Therapeutics

Oxalo Therapeutics is a private, preclinical biotech founded in 2018 and spun out from the University of Chicago. The company is pioneering a novel, microbiome-inspired peptide therapeutic platform to treat primary hyperoxaluria and other oxalate-related pathologies by promoting oxalate secretion in the gut. With an experienced leadership team combining deep nephrology expertise and business acumen, Oxalo is targeting a high-unmet medical need in a defined orphan disease population, with potential applications in broader kidney stone prevention.

Therapeutic Areas

Other Primary Hyperoxaluria Drugs